Coenzyme Q10 significantly reduced all-cause mortality (RR 0.64) and hospitalization for heart failure (RR 0.50) compared to control in patients with heart failure.
Meta-Analysis (n=3,763)
Does coenzyme Q10 added to conventional therapy reduce all-cause mortality and hospitalization in patients with heart failure?
Coenzyme Q10 supplementation added to standard therapy significantly reduces all-cause mortality and heart failure hospitalizations while improving functional capacity in patients with heart failure.
Relative Risk: 0.64 (95% CI 0.48–0.85)
p-value: p=0.002
BACKGROUND: The effectiveness and adverse effects of coenzyme Q10 for heart failure remain unclear owing to small sample sizes and variations in the quality of existing studies in literature. METHODS: The databases of EMBASE, PubMed, Web of Science, CINAHL databases, Scopus, Cochrane Central Register of Controlled Trials, VIP, Wanfang, and CNKI were searched for randomized controlled trials on the coenzyme Q10-assisted treatment of heart failure. Relevant literature was retrieved, data were extracted, and the risk of bias of the included studies was evaluated by two investigators independently using the Review Manager 5.4 software and the STATA 15 software. RESULTS: In total, 33 studies were included in this meta-analysis, which showed that all-cause mortality RR = 0.64, 95% CI (0.48, 0.85), P = 0.002; GRADE: moderate quality, hospitalization for heart failure RR = 0.50, 95% CI (0.37, 0.67), P < 0.00001; GRADE: moderate quality, New York Heart Association classification MD = - 0.29, 95% CI (- 0.39, - 0.19), P < 0.00001; GRADE: low quality, and brain natriuretic peptide level MD = - 91.97, 95% CI (- 103.11, - 80.83), P < 0.00001; GRADE: low quality were lower in the coenzyme Q10 group than in the control group. Meanwhile, left ventricular ejection fraction MD = 0.51, 95% CI (0.31, 0.71), P < 0.00001; GRADE: low quality and 6-min walk test result MD = 31.70, 95% CI (19.96, 43.43), P < 0.00001; GRADE: moderate quality were better than those in the control group. CONCLUSIONS: According to the existing evidence, coenzyme Q10 reduces all-cause mortality, hospitalization for heart failure, New York Heart Association classification, and brain natriuretic peptide level and improves left ventricular ejection fraction and 6-min walk test result in those with heart failure without major adverse effects. TRIAL REGISTRATION: This study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO, http://www.crd.york.ac.uk/prospero ), with the registration number CRD42023493184.
Xu et al. (Sat,) conducted a meta-analysis in Heart failure (n=3,763). Coenzyme Q10 vs. Conventional treatment with or without placebo was evaluated on All-cause mortality (RR 0.64, 95% CI 0.48, 0.85, p=0.002). Coenzyme Q10 significantly reduced all-cause mortality (RR 0.64) and hospitalization for heart failure (RR 0.50) compared to control in patients with heart failure.